MaxCyte signed five new SPLs in 2023 and we have seen continued momentum with ... compared to a loss of $5.8 million for the fourth quarter of 2022; stock-based compensation expense was $3.6 million ...
Fourth Quarter Earnings Conference Call Details MaxCyte plans to release final financial results for the fourth quarter and full year 2023 after the U.S. market close on Tuesday, March 12, 2024.
Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.
Q4 saw a 26% increase year-over-year, but full year revenue declined by 7%. Core Business Revenue: Experienced a 32% decrease ...
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...